 |
| |
|
Á¶¾ÆÅä´Ðĸ½¶ CHOATONIC CAP.
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
644601130
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹ÌȲ»öÀÇ ºÐ¸»ÀÌ µé¾î ÀÖ´Â »ó.ÇÏ °¥»öÀÇ °æÁú ݼ¿Á¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
300ĸ½¶(150ĸ½¶ X 2EA) |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 26¹Ð¸®±×·¥ |
500 ĸ½¶ |
8806446011301 |
8806446011363 |
|
| 26¹Ð¸®±×·¥ |
100 ĸ½¶ |
8806446011301 |
8806446011356 |
¼öÃâ¿ë |
| 26¹Ð¸®±×·¥ |
20 ĸ½¶ |
8806446011301 |
8806446011349 |
|
| 26¹Ð¸®±×·¥ |
120 ĸ½¶ |
8806446011301 |
8806446011332 |
|
| 26¹Ð¸®±×·¥ |
300 ĸ½¶ |
8806446011301 |
8806446011325 |
|
| 26¹Ð¸®±×·¥ |
150 ĸ½¶ |
8806446011301 |
8806446011318 |
|
|
| ÁÖ¼ººÐÄÚµå |
C36200ACH
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| ´ëÇ¥ÄÚµå |
8806446011301 |
| º¸°ü¹æ¹ý |
±â¹Ð¿ë±â, ½Ç¿Âº¸°ü(1¡30¡É) |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
(ĸ½¶Á¦)
ÀÚ¾ç°Àå, Çã¾àüÁú, À°Ã¼ÇÇ·Î, º´Áߺ´ÈÄ ¹ß¿¼º ¼Ò¸ð¼º Áúȯ, ÀӽżöÀ¯±â µîÀÇ ¿µ¾çº¸±Þ
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
(ĸ½¶Á¦)
15¼¼ ÀÌ»ó ¾î¸°ÀÌ ¹× ¼ºÀÎ : 1ȸ 2ĸ½¶À» 1ÀÏ 1¢¦2ȸ º¹¿ëÇÑ´Ù.
|
| °æ°í |
ÀӺο¡ ºñŸ¹Î A(·¹Æ¼³î)¸¦ 1ÀÏ 5,000 IUÀÌ»ó Åõ¿©ÇÏ´Â °æ¿ì¿¡´Â ¼±Ãµ¼º ±âÇüÀ» À¯¹ßÇÒ À§ÇèÀÌÀÖÀ¸¹Ç·Î ÀӽŠ3°³¿ù À̳» ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼º ÀÖ´Â ¿©¼º¿¡°Ô´Â ºñŸ¹Î A¸¦ 1ÀÏ 5,000 IU ÀÌ»óÅõ¿©ÇÏÁö ¾Ê´Â´Ù.(ºñŸ¹Î A°áÇÌÁõ ȯÀÚ´Â Á¦¿Ü)
|
| ±Ý±â |
1) °íÄ®½·Ç÷Áõ(hypercalcemia : Ç÷¾×Áß¿¡ Ä®½·ÀÌ °úÀ×À¸·Î Á¸ÀçÇÏ´Â »óÅÂ)ȯÀÚ, À¯À°Á¾Áõ(sarcoidosis), ½ÅÁúȯ ȯÀÚ
2) ÀÌ ¾à ¹× ÀÌ ¾à¿¡ Æ÷ÇÔµÈ ¼ººÐ¿¡ÀÇ °ú¹Î¹ÝÀÀ ȯÀÚ
3) 3°³¿ù ¹Ì¸¸ÀÇ ¿µ¾Æ
|
| ½ÅÁßÅõ¿© |
1) 12°³¿ù ¹Ì¸¸ÀÇ ¿µ¾Æ
2) ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í Àִ ȯÀÚ
3) °í¼ö»ê¿äÁõ(hyperoxaluria : ¿äÁß¿¡°ú·®ÀÇ ¼ö»ê¿°ÀÌ ¹è¼³µÇ´Â »óÅÂ) ȯÀÚ
4) ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ¿©¼º, ¼öÀ¯ºÎ
5) ¿Ü±¹¿¡¼ ÀÓ½ÅÀü 3°³¿ùºÎÅÍ ÀÓ½ÅÃʱâ 3°³¿ù±îÁö ºñŸ¹Î A¸¦ 1ÀÏ 10,000 IU ÀÌ»ó ¼·ÃëÇÑ ¿©¼ºÀ¸·ÎºÎÅÍ ÅÂ¾î³ ¾ÆÀÌ¿¡¼ ´ÉÇü³ú(Ò÷úþÒà, hindbrain : ¹è¾Æ¹ß»ýÃʱ⠽Űæ°üÀÇ ³»°ÀÌ È®ÀåµÇ¾î Çü¼ºµÇ´Â ºÎºÐ) µîÀ»Áß½ÉÀ¸·Î ÇÏ´Â ±âÇü¹ßÇö Áõ°¡°¡ ÃßÁ¤µÈ´Ù´Â ¿ªÇÐÁ¶»ç°á°ú°¡ ÀÖÀ¸¹Ç·Î ÀӽŠ3°³¿ù À̳» ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ»°¡´É¼ºÀÌ ÀÖ´Â ¿©¼º¿¡°Ô Åõ¿©ÇÒ °æ¿ì´Â ¿ë¹ý¿ë·®¿¡ ÁÖÀÇÇϰí ÀÌ ¾à¿¡ ÀÇÇÑ ºñŸ¹Î A Åõ¿©´Â 1ÀÏ 5,000 IU ¹Ì¸¸¿¡¸Ó¹°µµ·Ï ÇÏ´Â µî ÀûÀýÇÑ ÁÖÀǸ¦ ÇÑ´Ù.
|
| ÀÌ»ó¹ÝÀÀ |
1) ±¸¿ª, ±¸Åä,¼³»ç, °¡·Á¿òÁõ, °ÇÁ¶ÇÏ°í °ÅÄ£ ÇǺÎ, ÅëÁõ¼º °üÀýºÎÁ¾, ¹±Àº º¯, À§ºÎÆØ¸¸°¨, ¹è°¡ °ÅºÏÇÔ, º¯ºñ, ¹ßÁø, ¹ßÀû, ½Ä¿åºÎÁøµî
2) ÀÌ ¾àÀÇ Åõ¿©¿¡ ÀÇÇÏ¿© »ý¸®°¡ ¿¹Á¤º¸´Ù »¡¶óÁö°Å³ª ¾çÀÌ Á¡Á¡ ¸¹¾ÆÁú ¼ö ÀÖÀ¸¸ç, ÃâÇ÷ÀÌ ¿À·¡ Áö¼ÓµÉ ¼öµµ ÀÖ´Ù.
3) ¿¡½ºÆ®·Î°ÕÀÌ Æ÷ÇÔµÈ °æ±¸¿ë ÇÇÀÓÁ¦¸¦ º¹¿ëÇÏ´Â ¿©¼º ¶Ç´Â Ç÷Àü¼º ¼ÒÀÎÀÌ Àִ ȯÀÚ°¡ ºñŸ¹ÎE¸¦ º¹¿ëÇÒ °æ¿ì Ç÷ÀüÁõÀÇ À§ÇèÀÌ Áõ°¡µÉ ¼ö ÀÖ´Ù.
4) Àå±â°£ °í¿ë·®À» Åõ¿©ÇÒ °æ¿ì ³»¼ºÀÌ »ý±æ ¼ö ÀÖ´Ù.
5) ÇǸ®µ¶½ÅÀ» 1ÀÏ 500 mg¢¦2 gÀÇ ¿ë·®À¸·Î Àå±â°£ º¹¿ëÇÏ¸é °¨°¢½Å°æº´ ¶Ç´Â ½Å°æº´Áõ(neuropathy : ¸»ÃʽŰæ°èÀÇ ±â´ÉÀû Àå¾Ö ¶Ç´Â º´Àûº¯È)À̳ªÅ¸³¯ ¼ö ÀÖ´Ù.
6) ¿±»êÀÌ ºÎÁ·ÇÑ È¯ÀÚ¿¡°Ô ºñŸ¹Î B12¸¦ 1ÀÏ 10§¶ÀÌ»ó Åõ¿©ÇÒ °æ¿ì Ç÷¾×ÇÐÀû ÀÌ»ó¹ÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
7) °í¿ë·® Åõ¿©¿¡ ÀÇÇØ ¼Òȼº ±Ë¾çÀ» ÃËÁø½ÃŰ°í ´ç³»¼º ¼Õ»ó(glucosetolerance impairment : ½ÅüÀÇ Æ÷µµ´çÀ» ´ë»çÇÏ´Â ´É·Â Àå¾Ö), °í¿ä»êÇ÷Áõ(hyperuricemia, Ç÷¾×Áß¿¡ ¿ä»êÀÌ °úÀ×À¸·Î Á¸ÀçÇÏ´Â »óÅÂ), °£¼Õ»óÀ»ÀÏÀ¸Å³ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
·¹º¸µµÆÄ
|
| Àû¿ë»óÀÇ ÁÖÀÇ |
1) Á¤ÇØÁø ¿ë¹ý¿ë·®À» Àß Áöų °Í
2) 1°³¿ù Á¤µµ Åõ¿©ÇÏ¿©µµ Áõ»óÀÇ °³¼±ÀÌ ¾ø°Å³ª ¾Ç鵃 °æ¿ì¿¡´Â ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »óÀÇÇÑ´Ù
3) ÀÌ ¾à¿¡ ÇÔÀ¯µÈ ºñŸ¹Î A´Â Á¤»óÀûÀÎ ½ÄÀÌ¿¡¼ÃæºÐÈ÷ °ø±ÞµÇ¹Ç·Î º¸Á¶¿ä¹ýÀÇ ¿ë·®Àº 1ÀÏ 5000 IU ÀÌ»óÀ»³ÑÁö ¾Êµµ·Ï ÇÑ´Ù.
4) °¢Á¾ ¿ä°Ë»ç½Ã¿¡ Ç÷´çÀÇ °ËÃâÀ» ¹æÇØÇÒ ¼ö ÀÖ´Ù
5) ¿ä¸¦ Ȳ»öÀ¸·Î º¯ÇÏ°Ô ÇÏ¿© ÀÓ»ó°Ë»çÄ¡¿¡ ¿µÇâÀ» ÁÙ ¼ö ÀÖ´Ù.
6) ºñŸ¹Î D´Â ¸ðÀ¯·Î ºÐºñµÇ¾î ½Å»ý¾Æ¿¡°Ô °íÄ®½·Ç÷ÁõÀ»ÀÏÀ¸Å³ ¼ö ÀÖ´Ù
|
| º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ |
1) ¾î¸°ÀÌÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇÑ´Ù.
2) Á÷»ç±¤¼±À» ÇÇÇÏ°í µÉ ¼ö ÀÖÀ¸¸é ½À±â°¡ Àû°í ¼´ÃÇÑ °÷¿¡ ¹ÐÀüÇÏ¿© º¸°üÇÑ´Ù.
3) ¿À³²¿ëÀ» ÇÇÇϰí, ǰÁúÀ»º¸È£À¯ÁöÇϱâ À§ÇØ ´Ù¸¥ ¿ë±â¿¡ ³ÖÁö ¾Ê´Â´Ù.
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| ¼ººÐÄÚµå |
M083515/¿¡¸£°íÄ®½ÃÆä·Ñ°ú¸³ 0.118¹Ð¸®±×·¥ /
M040751/¿°»êÇǸ®µ¶½Å 5¹Ð¸®±×·¥ /
M040442/¿±»ê 0.1¹Ð¸®±×·¥ /
M095198/À̼ҷÎÀ̽Š5¹Ð¸®±×·¥ /
M083188/½Ã¾Æ³ëÄڹ߶ó¹Î0¤ý1% 0.5¹Ð¸®±×·¥ /
M040064/´ÏÄÚÆ¾»ê¾Æ¹Ìµå 10¹Ð¸®±×·¥ /
M095199/Æ®¸®ÇÁÅäÆÇ 5¹Ð¸®±×·¥ /
M095200/¹ß¸° 5¹Ð¸®±×·¥ /
M095773/ºñŸ¹ÎA 1000¾ÆÀÌ.À¯ /
M089686/ÃÊ»êÅäÄÚÆä·Ñ50% 10¹Ð¸®±×·¥ /
M100358/¿°»ê¸®½Å 25¹Ð¸®±×·¥ /
M071150/Áú»êÄ¡¾Æ¹Î 2.5¹Ð¸®±×·¥ /
M082857/Á¦ÇǾƽºÄÚ¸£ºó»ê 26¹Ð¸®±×·¥ /
M090697/Æ®·¹¿À´Ñ 5¹Ð¸®±×·¥ /
M082328/·ÎÀ̽Š9.15¹Ð¸®±×·¥ /
M040133/¸®º¸Çöóºó 1.5¹Ð¸®±×·¥ /
M040150/µð¿¤¸ÞÄ¡¿À´Ñ 9.2¹Ð¸®±×·¥ /
M085066/Æä´Ò¾Ë¶ó´Ñ 5¹Ð¸®±×·¥ /
M040679/ÆÇÅäÅÙ»êÄ®½· 2.5¹Ð¸®±×·¥ /
|
| ÁÖ¼ººÐÄÚµå |
C36200ACH
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| ´ëÇ¥ÄÚµå |
8806446011301 |
| BIT ¾àÈ¿ºÐ·ù |
±âŸ ºñŸ¹Î/¿µ¾çÁ¦·ù (Other Vitamins & Nutritional Supplements)
|
| ATC ÄÚµå |
Amino acids/carbohydrates/minerals/vitamins, combinations / V06DE
[ÄÚµåºÐ·ù»ó¼¼¼³¸í]
[ATCÄÚµå¿¹Ãø]
|
| º¹ÁöºÎºÐ·ùÄÚµå |
329 (±âŸÀÇ ÀÚ¾ç°À庯ÁúÁ¦ )
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Aµî±Þ
(ascorbic acid;cyanocobalamin;ergocalciferol;folic acid; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Ascorbic Acid¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Calcium¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Cyanocobalamin¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Folic acid¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Nicotinamide¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Calcium¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. More than 500 human proteins are known to bind or transport calcium. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Parathyroid hormone (secreted from the parathyroid gland) regulates the resorption of Ca2+ from bone. Calcitonin stimulates incorporation of calcium in bone, although this process is largely independent of calcitonin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium. Low calcium intake may also be a risk factor in the development of osteoporosis. The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast. The currently recommended calcium intake is 1,500 milligrams per day for women not taking estrogen and 800 milligrams per day for women on estrogen. There is close to 300 milligrams of calcium in one cup of fluid milk. Calcium carbonate is currently the best and least expensive form of calcium supplement available.
Cyanocobalamin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Vitamin B12 is used in the body in two forms: Methylcobalamin and 5-deoxyadenosyl cobalamin. The enzyme methionine synthase needs methylcobalamin as a cofactor. This enzyme is involved in the conversion of the amino acid homocysteine into methionine. Methionine in turn is required for DNA methylation. 5-Deoxyadenosyl cobalamin is a cofactor needed by the enzyme that converts L-methylmalonyl-CoA to succinyl-CoA. This conversion is an important step in the extraction of energy from proteins and fats. Furthermore, succinyl CoA is necessary for the production of hemoglobin, the substances that carries oxygen in red blood cells.
Ergocalciferol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Vitamin D2 is the form of vitamin D most commonly added to foods and nutritional supplements. Vitamin D2 must be transformed (hydroxylated) into one of two active forms via the liver or kidney. Once transformed, it binds to the vitamin D receptor that then leads to a variety of regulatory roles. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma. Vitamin D2 and its analogs appear to promote intestinal absorption of calcium through binding to a specific receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.
|
| Pharmacology |
Cyanocobalamin¿¡ ´ëÇÑ Pharmacology Á¤º¸ Cyanocobalamin (Vitamin B12) is a water-soluble organometallic compound with a trivalent cobalt ion bound inside a corrin ring. It is needed for nerve cells and red blood cells, and to make DNA. Vitamin B12 deficiency is the cause of several forms of anemia.
Ergocalciferol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Used in the treatment of hypcalcemia and in dialysis-dependent renal failure. Ergoalcifediol (Vitamin D2) is a fat soluble steroid hormone precursor of vitamin D that contributes to the maintenance of normal levels of calcium and phosphorus in the bloodstream.
|
| Metabolism |
Cyanocobalamin¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Methylenetetrahydrofolate reductase
Ergocalciferol¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 24A1 (CYP24A1)
|
| Absorption |
Cyanocobalamin¿¡ ´ëÇÑ Absorption Á¤º¸ Readily absorbed in the lower half of the ileum.
Ergocalciferol¿¡ ´ëÇÑ Absorption Á¤º¸ Readily absorbed from small intestine (proximal or distal), requires presence of bile salts.
|
| Toxicity |
Cyanocobalamin¿¡ ´ëÇÑ Toxicity Á¤º¸ Anaphylactic reaction (skin rash, itching, wheezing)-after parenteral administration. ORL-MUS LD50 > 8000 mg/kg
Ergocalciferol¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50 = 23.7 mg/kg (Orally in mice); LD50 = 10 mg/kg (Orally in rats ); Nausea, vomiting and diarrhea, weight loss, irritability, weakness, fatigue, lassitude, and headache.
|
| Drug Interactions |
Calcium¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Alendronate Formation of non-absorbable complexesAmprenavir The antiacid decreases the absorption of amprenavirAtazanavir This gastric pH modifier decreases the levels/effects of atazanavirChloroquine The antiacid decreases the absorption of chloroquineCiprofloxacin Formation of non-absorbable complexesDapsone Formation of non-absorbable complexesDelavirdine The antiacid decreases the effect of delavirdineDemeclocycline Formation of non-absorbable complexesDoxycycline Formation of non-absorbable complexesEnoxacin Formation of non-absorbable complexesFosamprenavir The antiacid decreases the absorption of amprenavirGrepafloxacin Formation of non-absorbable complexesIbandronate Formation of non-absorbable complexesIndinavir The antiacid decreases the absorption of indinavirItraconazole The antacid decreases the effect of the imidazoleKetoconazole The antacid decreases the effect of the imidazoleLevofloxacin Formation of non-absorbable complexesLevothyroxine Calcium decreases absorption of levothyroxineLomefloxacin Formation of non-absorbable complexesMethacycline Formation of non-absorbable complexesMinocycline Formation of non-absorbable complexesMoxifloxacin Formation of non-absorbable complexesNorfloxacin Formation of non-absorbable complexesOfloxacin Formation of non-absorbable complexesOxytetracycline Formation of non-absorbable complexesPefloxacin Formation of non-absorbable complexesPolystyrene sulfonate Formation of non-absorbable complexesRisedronate Formation of non-absorbable complexesTetracycline Formation of non-absorbable complexesTrovafloxacin Formation of non-absorbable complexesClodronate Formation of non-absorbable complexesEtidronic acid Formation of non-absorbable complexesMycophenolate mofetil Formation of non-absorbable complexesTemafloxacin Formation of non-absorbable complexes
Cyanocobalamin¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
Ergocalciferol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Calcium¿¡ ´ëÇÑ Description Á¤º¸ Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium. Low calcium intake may also be a risk factor in the development of osteoporosis. The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast.
Cyanocobalamin¿¡ ´ëÇÑ Description Á¤º¸ Cyanocobalamin (commonly known as Vitamin B12) is the most chemically complex of all the vitamins. Cyanocobalamin's structure is based on a corrin ring, which, although similar to the porphyrin ring found in heme, chlorophyll, and cytochrome, has two of the pyrrole rings directly bonded. The central metal ion is Co (cobalt). Cyanocobalamin cannot be made by plants or by animals, as the only type of organisms that have the enzymes required for the synthesis of cyanocobalamin are bacteria and archaea. Higher plants do not concentrate cyanocobalamin from the soil and so are a poor source of the substance as compared with animal tissues. Cyanocobalamin is naturally found in foods including meat (especially liver and shellfish), eggs, and milk products. [HMDB]
Ergocalciferol¿¡ ´ëÇÑ Description Á¤º¸ Ergocalciferol (Vitamin D2) is a derivative of ergosterol formed by ultraviolet rays breaking of the C9-C10 bond. It differs from cholecalciferol in having a double bond between C22 and C23 and a methyl group at C24. [PubChem]
Nicotinamide¿¡ ´ëÇÑ Description Á¤º¸ An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. [PubChem]
|
| Dosage Form |
Calcium¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralLiquid DentalLiquid IntravenousLiquid OralLiquid SublingualPaste DentalPowder OralPowder, for solution OralSolution IntramuscularSolution IntravenousSolution OralSolution / drops OralSyrup OralTablet OralTablet, chewable Oral
Cyanocobalamin¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralLiquid IntramuscularLiquid OralPowder OralSolution IntramuscularTablet OralTablet, extended release Oral
Ergocalciferol¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule Oral
|
| Drug Category |
Cyanocobalamin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antianemic AgentsEssential VitaminVitamins (Vitamin B Complex)
Ergocalciferol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antihypocalcemic AgentsAntihypoparathyroid AgentsBone Density Conservation AgentsEssential VitaminVitaminsVitamins (Vitamin D)
Nicotinamide¿¡ ´ëÇÑ Drug_Category Á¤º¸ Vitamin B Complex
|
| Smiles String Canonical |
Calcium¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ Not Available
Cyanocobalamin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ [Co+3].[C-]
Ergocalciferol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C)C(C)C=CC(C)C1CCC2C1(C)CCCC2=CC=C1CC(O)CCC1=C
Nicotinamide¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC(=O)C1=CC=CN=C1
|
| Smiles String Isomeric |
Calcium¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ Not Available
Cyanocobalamin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ [Co+3].[C-]
Ergocalciferol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C
Nicotinamide¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NC(=O)C1=CC=CN=C1
|
| InChI Identifier |
Calcium¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ Not Available
Cyanocobalamin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C62H90N13O14P.CN.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;1-2;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;/q;-1;+3/p-1/t31?,34-,35-,36-,37+,41+,52?,53?,56?,57+,59-,60+,61+,62+;;/m1../s1/fC62H89N13O14P.CN.Co/h69,85H,63-68H2;;/q-1;2m/b42-23-,54-32-,55-33-;;
Ergocalciferol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1
Nicotinamide¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)/f/h7H2
|
| Chemical IUPAC Name |
Calcium¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ Not Available
Cyanocobalamin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ Not Available
Ergocalciferol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
Nicotinamide¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ pyridine-3-carboxamide
|
| Drug-Induced Toxicity Related Proteins |
LYSINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Tamm-Horsfall protein Drug:Lysine Toxicity:persisting acute renal failure . [¹Ù·Î°¡±â] METHIONINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:NMDA receptor-regulated protein Drug:methionine Toxicity:cerebrovascular disease. [¹Ù·Î°¡±â] Replated Protein:Cystathionine beta-synthase Drug:methionine Toxicity:lipoprotein peroxidation and platelet aggregation. [¹Ù·Î°¡±â] Replated Protein:Methylenetetrahydrofolate reductase Drug:methionine Toxicity:lipoprotein peroxidation and platelet aggregation. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2020-05-11
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|